Can a daily pill douse the Sun's pain for people with EPP?
NCT ID NCT06971900
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This phase 2a trial tests whether an experimental oral drug called PORT-77 can lower levels of protoporphyrin IX (PPIX) in the blood of adults with erythropoietic protoporphyria (EPP). People with EPP experience severe pain and skin reactions after even brief sun exposure. The study will compare PORT-77 against a placebo to see if it safely reduces PPIX, a key driver of light sensitivity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral drug called PORT-77
- What this could lead to
- If it works, PORT-77 could offer a daily pill to reduce painful light reactions in people with erythropoietic protoporphyria.
- What could go wrong
- This is a small, early-phase trial with only 28 participants. It primarily measures a biomarker (PPIX levels) rather than direct symptom relief, so success is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHROPOIETIC PROTOPORPHYRIA (EPP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion
Tempe, Arizona, 85283, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare sun allergy: bitopertin offered to patients with no options
- New study aims to unlock mysteries of rare sun allergy disorders
- New drug aims to let sunlight-sensitive patients enjoy the sun longer
- New pill could let EPP patients enjoy the sun without pain
- New pill could let Sun-Sensitive patients enjoy the outdoors